XLO Stock — Xilio Therapeutics Inc.: Cash, EV, Pipeline

Share price

$9.13

Market cap

$60.1M

Cash

$136.0M

Enterprise value

-$75.9M

Balance sheet

Cash	$136.0M
Debt	$0.0M
Net cash	$136.0M
Enterprise value	-$75.9M
Basic shares	6.6M shares
Fully diluted shares	30.2M shares
Fully diluted market cap	$276.1M
Cash per share	$20.61

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading XLO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	XTX301	Phase 1/2	Advanced Solid Tumor	—
Dec 13, 2029 - Jan 24, 2030	XTX501	Phase 1/2	Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced Solid Tumor	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

efarindodekin alfa

Phase 2 · Active Modality: biologic (masked IL-12 immunotherapy)

Target IL-12

Partnerships Gilead Sciences: exclusive global license (Mar 2024; $30M upfront; $75M transition fee on opt-in after Phase 1 + initial Phase 2 data package; up to $500M milestones; high-single-to-mid-teens royalties)

Indications

Advanced solid tumors (Phase 2)

Catalysts

— H1 2027

Status note Ongoing Phase 2 monotherapy; Xilio conducts development through initial Phase 2.

vilastobart

Phase 2 · Active Modality: biologic (masked, Fc-enhanced anti-CTLA-4 monoclonal antibody)

Target CTLA-4

Partnerships Roche: 2023 co-funded clinical trial collaboration (clinical supply agreement; atezolizumab combination in MSS mCRC; $8M cost-sharing received)

Indications

Microsatellite stable metastatic colorectal cancer (with atezolizumab) (Phase 2)

Status note Phase 2 complete in MSS mCRC (without liver metastases); seeking partner to maximize value.

XTX501

Preclinical · Active Modality: biologic (bispecific PD-1 / masked IL-2 antibody fusion protein)

Target PD-1 / IL-2

Indications

Metastatic NSCLC and other solid tumors (Preclinical)

Catalysts

— mid-2026
— H2 2026
— H2 2027

Status note IND-enabling studies ongoing.

AbbVie collaboration program

Preclinical · Active Modality: biologic (masked antibody-based immunotherapy)

Partnerships AbbVie: Feb 2025 collaboration, license and option agreement for up to four masked immunotherapy programs ($42M upfront; up to ~$2.1B contingent; high-single/mid-single-digit royalties); plus Initial Option Program (masked T cell engagers) and up to two Additional Option Programs

Status note Collaboration program preclinical through lead generation; $5M and $6M development milestones achieved (Q4 2025, Q2 2026).

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	XTX301
Lead indication	Advanced Solid Tumor
Lead phase	Phase 1/2
Active trials	2
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05684965	Phase 1/2	Recruiting	Sponsor	Xilio Development, Inc.	—	Advanced Solid Tumor	—
NCT07688577	Phase 1/2	Not yet recruiting	Sponsor	Xilio Development, Inc.	—	Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced Solid Tumor	—
NCT07765836	Phase 2	Not yet recruiting	Collaborator	Massachusetts General Hospital	—	Pancreatic Cancer Metastatic	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Xilio Development, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	592,300	+592,300	0.11%	2026-08-14
Frazier Life Sciences	422,505	no change	0.09%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

XLO — Xilio Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders